Publications

• R.M. Novak and D.C. Robinson: Observations on the reproduction and ecology of the tropical montane toad, Bufo holdridgei Taylor in Costa Rica. Rev. Biol. Trop.,23(2): 213-237, 1975.
• R.M. Novak, D. Ou, R. Sulo and Y. Chen: Variable response to intravenous gamma globulin in a patient with autoimmune neutropenia, thrombocytopenia and pemphigoid. Southern Medical Journal. 81(5):653-655, 1988.
• R.M. Novak, B. Duarte and J.B. Leikin: Use of thrombolytic therapy in axillary-subclavian vein thrombosis. Am J. Emergency Med. 6(2):120-123, 1988.
• R.M. Novak, E. Polisky, W.M. Janda and C.R. Libertin: Osteomyelitis caused by Rhodococcus equi in a renal transplant patient. Infection. 16: 56-58, 1988.
• R.D. Pryka, R.M.Novak, D.K. Wagner and K.A. Rodvold: Clinical Pharmacokinetics of Daptomycin. DICP, Ann Pharmacotherapy. 24:255-6, 1990.
• R.M. Novak , T.J. Holzer , M. M. Kennedy , C.A. Heynen and G.Dawson: The effect of Interleukin 4 (BSF-1) on infection of peripheral blood monocyte-derived macrophages with HIV-1
• AIDS Res. Human Retroviruses. 6: 973-976, 1990.
• R.M. Novak, T.J. Holzer and C.R. Libertin. Oxidative response and phagocytic killing of clinical and laboratory strains of Enterococcus faecalis.  Diagnostic Microbiol Inf Dis. 17: 1-6. 1993.
• L.H. Danziger, T.P. Kanyok and R.M. Novak. Treatment of cryptosporidial diarrhea in an AIDS patient with paromomycin. Ann Pharmacotherapy 27:1460-1462. 1993
• C.Pidgeon, R.J. Markovich, M.L. Liu, T.J. Holzer, R.M. Novak and K.A. Keyer. Anti-HIV Active Phospholipids: Drugs conjugated to the Glycerobackbone of Phospholipids. J. Biological Chemistry, 268: 7773-7778, 1993
• Ang, G.A.T., Janda, W.M., R.M. Novak.and Gerardo, L.: Negative Images of Mycobacteria in the Lympho Node Aspiration Biopsies of a Patient With AIDS. Diagnostic Cytopathology, 9: 325-328, 1993.
• D.L. Pitrak, P.M. Bak, P.L. DeMarais, R.M. Novak and B.R. Andersen.: Depressed Neutrophil Superoxide Production in Human Immunodeficiency Virus Infection. J. Infect. Dis. 167: 1406-1410. 1993.
• T.J. Holzer, C.A. Heynen, R.M. Novak, D.L. Pitrak and G.J. Dawson. Frequency of cells positive for HIV-1 p24 antigen assessed by flow cytometry. J. AIDS,7: S3-S5. 1993.
• M. Ghassemi, B.R. Andersen, M.V. Reddy, P.R.J. Gangadharum, G. Spear, and R.M. Novak. Interaction Between Human Immunodeficiency Virus and Mycobacterium avium complex in monocytoid cells results in reciprocal enhancement. J. Infect. Dis., 171:68-73. 1995.
• E.M. Martin, K.M. Mullane, T.E. Harris, D.L. Pitrak, K.J. Pursell, R.M. Novak, R.F. Farinpour and M.E. Menken. Self-reported depression and HIV-1 disease severity: gender differences. HIV Infect. Women. Feb 22-24, p.94.1995.
• O.J.Cohen, G. Pantaleo, M. Holodniy, S. Schnittman, M. Niu, C. Graziosi, G.N. Pavlakis, J. Lalezari, J.A. Bartlett, R.T. Steigbigel, J. Cohn, R. Novak, D. McMahon and A.S. Fauci. Decreased HIV-1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue. Proc. Nat. Acad. Sci., 92:6017-6021. 1995.
• E.M. Martin, D.L. Pitrak, K.M. Mullane, K.J. Pursell, and R.M. Novak, Delayed recognition memory span in HIV-1 infection.  Journal of the International Neuropsychological Society 1:575-580. 1995.
• E.M. Martin, D.L. Pitrak L.C. Robertson, R.M. Novak, K.M. Mullane, and K.J. Pursell. Global-local analysis in HIV-1 infection.  Neuropsychology, 9:102-109. 1995.
• N.L. McCain, J.M. Zeller, D.F. Cella, P.A. Urbanski and R.M. Novak. The influence of stress management training in HIV disease. Nursing Research, 45: 246-53. 1996.
• O.J.Cohen, G. Pantaleo, M. Holodniy, C.H. Fox, J.M. Orenstein, S. Schnittman, M. Niu, C. Graziosi, G.N. Pavlakis, J. Lalezari, J.A. Bartlett, R.T. Steigbigel, J. Cohn, R. Novak, D. McMahon and A.S. Fauci. Anitretroviral monotherapy in early stage Human Immunodeficiency Virus Disease has no detectable effect on virus load in peripheral blood and lymph nodes. J. Infect. Dis. 173:849-56. 1996.
• C.A. Gentry, K.A. Rodvold, R.M. Novak, R.C. Hershow and O.J. Naderer. Retrospective evaluation of therapies for Staphylococcus aureus endocarditis. Pharmacotherapy, 17: 990-7. 1997.
• J.A. Bartok, E.M. Martin, D.L. Pitrak, R.M. Novak, K.J. Pursell, K.M. Mullane and M. Harrow. Working memory deficits in HIV-seropositive drug users. J. Int. Neuropsychol. Soc., 3: 451-6. 1997.
• J.G.Timpone, D.J. Wright, N.Li, M.J. Egorin, M.E. Enama, J. Mayers, G. Galetto, and the DATRI 004 Study Group. The safety and pharmacokinetics of single agent and combination therapy with megesterol acetate and dronabinol for the treatment of HIV wasting syndrome. AIDS Research Human Retroviruses. 13:305-315. 1997.
• E.M. Martin, D.L. Pitrak, K.J. Pursell, B.R. Andersen, K.M. Mullane and R.M. Novak. Information processing and antiretroviral therapy in HIV-1 infection. J. Int. Neuropsychol. Soc., 4: 329-35. 1998.
• A.L. Landay, J. Bethel, S.Schnittman for the DATRI 003 Study Group. Phenotypic variability of lymphocyte populations in peripheral blood and lymph nodes from HIV-infected individuals and the impact of antiretroviral therapy. AIDS Research Human Retroviruses. 14:445-451. 1998.
• M.T. Niu, J. Bethel, M. Holodniy, H.C. Standiford, S.M. Schnittman and the DATRI 002 Study Group. Zidovudine treatment in patients with primary (acute) Human Immunodeficiency Virus Type 1 infection: a randomized, double blinded, placebo-controlled trial. J. Infect. Dis., 178:80-91. 1998.
• E.M. Martin, D.L. Pitrak, R.M. Novak, K.J. Pursell, and K.M. Mullane. Reaction times are faster in HIV-seropositive patients on antiretroviral therapy: a preliminary report. J. Clin. Exp. Neuropsychol. 21:730-735. 1999.
• M. Ghassemi, B.R. Andersen, K.A. Roebuck, M.F. Rabbi, J.M.D. Plate, and R.M. Novak.Mycobacterium avium Complex Activates Nuclear Factor kB via Induction of Inflammatory Cytokines. Cellular Immunology, 191:117-123, 1999.
• M. Ghassemi, F.K. Asadi, B.R. Andersen, and R.M. Novak. Mycobacterium avium Induces HIV Upregulation Through Mechanisms Independent of Cytokine Induction. AIDS Research Human Retroviruses, 16(5):435-440. 2000
• R. Farinpour, E.M. Martin, M. Seidenburg, D.L. Pitrak, K.J. Pursell, K.M. Mullane, R.M. Novak, M. Harrow. Verbal working memory in HIV-seropositive drug users. J. Int. Neuropsychol Soc. 6(5):548-55. 2000.
• R.M. Novak, J. Koirala, M.L. Sirdar, N. D’ Alfonso-Laghi, L. Moreira, D.L. Pitrak, and M. Ghassemi, Lymphoproliferative Responses to Mitogens and Prepared Antigens of M. avium Complex in Patients with HIV Infection. J. Clin. Immunol., 20:62-67.2000.
• R.D. MacArthur, L. Chen, D.L. Mayers, C.L. Besch, R. Novak, M. van den Berg-Wolf, T. Yurik, G. Peng, B. Scmetter, B. Brizz, D. Abrams. The rationale and design of the CPCRA 058 FIRST (Flexible initial retrovirus suppression therapies) trial. Controlled Clinical Trials, 22:176-190. 2001.
• D.L. Pitrak, J. Bolanos, R.Hershow, R.M. Novak. Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. AIDS, 15(10): 1317-1319. 2001.
• J.K.Keithley, B. Swanson, J.M. Zeller, B.E. Sha, M. Cohen, R. Hershow and R.Novak. Comparison of standard and immune-enhancing oral formulas in asymptomatic HIV-infected persons: a multicenter randomized controlled clinical trial. J. Parenteral and Enteral Nutr., 26, 6-14.2002.
• W.M. Janda, P. Tipirneni and R.M. Novak. Brevibacterium casei bacteremia and line sepsis in patients with AIDS. J. Infection, 46 (1): 61-64.2003.
• M. Ghassemi, R. M. Novak, M. F. Khalili and J. Zhou Viable Mycobacterium aviumis required for the majority of human immunodeficiency virus-induced upregulation in monocytoid cells. Journal of Medical Microbiology, 52:1–6. 2003.
• M. P. Pai, C. A. Schriever, M. Diaz-Linares, R. M. Novak, K. A. Rodvold,.Sex-Related Differences in the Pharmacokinetics of Once Daily Saquinavir Sof:592-599.2004.
• M. R. Zariffard, S. Harwani,  R. M. Novak, P. J. Graham, J. Xin, and G. T. Spear Trichomonas vaginalis infection activates cells through toll-like receptor 4. Clin. Immunol., 111(1):103-7.2004.
• E. M. Martin, R. M Novak, M. Fendrich, J. Vassileva,R. Gonzalez, S. Grbesic, G. Nunnally, and L. Sworowski. Stroop Performance in Drug Users Classified by HIV and Hepatitis C Virus Serostatus. Journal of the International Neuropsychological Society, 10(2):298-300.2004.
• RD MacArthur, L Chen, G Peng, RM Novak, M van den Berg-Wolf, M Kozal, L Besch, T Yurik, B Schmetter, C Henley, M Dehlinger and the CPCRA 058 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Efficacy and Safety of Abacavir plus Lamivudine versus Didanosine plus Stavudine when Combined with a Protease Inhibitor, a Non-Nucleoside Reverse Transcriptase Inhibitor or Both in HIV-1 Positive Antiretroviral-Naive Persons HIV Clinical Trials, Nov-Dec;5(6):361-70. 2004.
• Richard M. Novak, Li Chen, Rodger D. MacArthur, John Baxter, Kathy Huppler Hullsiek, Grace Peng, Ying Xiang, Christopher Henley, Barry Schmetter, Jonathan Uy, Mary van den Berg-Wolf, Michael Kozal and the CPCRA 058 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Prevalence of Antiretroviral Drug Resistance Mutations in Chronically HIV-Infected, Treatment Naïve Participants in the CPCRA FIRST Study: Implications for Routine Resistance Screening Prior to Initiating Antiretroviral Therapy. Clinical Infectious Diseases 40:468–74. 2005.
• Bradford N. Bartholow, Susan Buchbinder, Connie Celum, Vamshidar Goli, Beryl Koblin, Michael Para, Michael Marmor, Richard M. Novak, Kenneth Mayer, Catherine Creticos, Patti Orozco-Cronin, Vladimir Popovic,  and Timothy D. Mastro for the VISION/VAX004 Study Team. HIV Sexual Risk Behavior over 36-Months of Follow-up in the World’s First HIV Vaccine Efficacy Trial. J Acquir Immune Defic Syndr; 39:90–101. 2005
• M. Reza Zariffard, RM Novak, N. Lurain, B.E. Sha, P. Graham and G. T. Spear. Induction of TNF-a Secretion and Expression of Toll-Like Receptors 2 and 4 by Genital tract Secretions from Women with Bacterial Vaginosis. J. Infect. Dis., 191:1913-21. 2005
• R. Gonzalez, J. Vassileva, A. Bechara, S. Grbesic, L. Sworowski, R.M. Novak, G. Nunnally and E. Martin. The influence of executive functions, sensation seeking, and HIV serostatus on risky sexual practices of substance-dependent individuals. J. Int. Neuropsychol. Soc. 11(2):121-131. 2005
• Meghan A. Jendrysik, Mahmood Ghassemi, Parrie J. Graham, Lucy A. Boksa, Richard M. Novak. Human cervicovaginal lavage fluid contains an inhibitor of HIV binding to dendritic cell-specific intracellular adhesion molecule 3-grabbing nonintegrin. J. Infect. Dis. 192:630-9. 2005
• Michael J. Kozal, Katherine Huppler Hullsiek, Robert Leduc, Richard M Novak, Rodger D MacArthur, Jody Lawrence, and John D Baxter for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).  Prevalence and Impact of HIV-1 Protease Codon 33 Mutations and Polymorphisms in Treatment-Naïve and Treatment-Experienced Patients Enrolling in Clinical Trials. Antiviral Ther. 11(4):457-63. 2006.
• RD MacArthur, RM Novak, G Peng, L Chen, Y Xiang, K Huppler Hullsiek, MJ Kozal, M van den Berg-Wolf, C Henely, B Schmetter, M Dehlinger for the CPCRA 058 Study Team and the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA)Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens as Initial Therapy:  Results of the CPCRA 058 FIRST Study. Lancet, 368 (9553): 2107-9. 2006.
• JE Cummins Jr., M Denniston, KH Mayer, R Pickard, RM Novak P Graham, M Gurwith, K Orelind, ML Ackers, and CS Dezzutti. Mucosal Innate Immune Factors in Secretions from High Risk Individuals Immunized with a Bivalent gp120 Vaccine. AIDS Research Human Retroviruses, 23(5): 748-54. 2007.
• J Uy, J Brooks, R Baker, M Hoffman, A Moorman, R Novak, and the HOPS Investigators. HIV Genotypic Resistance Testing to Optimize Antiretroviral Prescribing: Is There Room for Improvement? Antiviral Therapy, 12:957-962. 2007
• RM Novak, BA Donoval, PJ Graham, LA Boksa, G Spear, RC Hershow, HY Chen and A Landay. Lactoferrin, Secretory Leukocyte Protease Inhibitor and RANTES (regulated on activation, normal T cell expressed and secreted) in the Genital Tract of Sexually High Risk, HIV-seronegative Women and the effect of coexisting vaginoses. Clin. Vaccine Immunol. Sep;14(9):1102-7. 2007.
• JA Schneider, SA Alam, M Ackers, B Parekh, HY Chen, P Graham, M Gurwith, K Mayer, RM Novak. Mucosal HIV Binding Antibody and Neutralizing Activity among High-Risk HIV-Uninfected Female HIV Vaccine Trial Participants, J. Infect. Dis., 196:1637-44. 2007.
• MJ Kozal, K Huppler Hullsiek, RD MacArthur, M van den Berg-Wolf, G Peng, Y Xiang, JD Baxter, J Uy, EE Telzak and RM Novak for the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). The Incidence of HIV Drug Resistance and Its Impact on Progression of HIV Disease Among Antiretroviral Naïve Participants Started on Three Different Antiretroviral Therapy Strategies. HIV Clin Trials, 27. 8 (6): 357-370. 2007.
• D Mares, JA Simoes, RM Novak and GT Spear: TLR2-Mediated Cell Stimulation in Bacterial Vaginosis. Journal of Reproductive Immunology, 77(1):91-99. 2008
• FH Priddy, D Brown, J Kublin, K Monahan, DP Wright, J Lalezari, S Santiago, M Marmor, M Lally, RM Novak, J Brown, P Kulkarni, SA Dubey, LS Kierstead, DR Casimiro, R Mogg, MJ DiNubile, JW Shiver, RY Leavitt, MN Robertson, DV Mehrotra, E Quirk For the Merck V520-016 Study Group
•   Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type-5 HIV-1 Clade B gag/pol/nef Vaccine  in Healthy Adults. Clin Infect Dis. Jun 1;46(11):1769-81. 2008
• P Patel, DL Hanson, PS Sullivan, RM Novak, AC Moorman, TC Tong, SD Holmberg,JT Brooks.
• Incidence of cancers among HIV-infected persons in the United States, 1992-2003, Ann Intern Med. May 20;148(10):728-36. 2008
• A Lavie, Y Su, M Ghassemi, RM Novak, M Caffrey, N Sekulic, C Monnerjahn, M Konrad and JL Cook. Restoration of the Antiviral Activity of AZT Against AZT-Resistant HIV by Delivery of Engineered Thymidylate Kinase to T cells. J. General Virology, 89(pt 7):1672-9. 2008.
• J. Koirala, A Adamski, L. Koch, D Steuber, M El-Azizi, NM. Khardori, M Ghassemi, and RM Novak. Interferon gamma receptors in HIV-1 infection. Aids Res. Hum. Retroviruses 2008. Aug;24(8):1097-102.
• M van den Berg-Wolf, K Huppler Hullsiek, G Peng, MJ Kozal, RM Novak, L Chen, LR Crane, and RD MacArthur for the CPCRA 058 Study Team, the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).Virologic, Immunologic, Clinical, Safety, and Resistance Outcomes from a Long-term Comparison of Efavirenz-Based Versus Nevirapine-Based Antiretroviral Regimens as Initial Therapy in HIV-1 Infected Persons. HIV Clinical Trials. 2008 Sep-Oct;9(5):324-36.
• B. Simen, JF Simons, K Huppler-Hullsiek, RM Novak, RD MacArthur, JD Baxter, C Huang, C Lubeski, GS Turenchalk, MS Braverman, B Desany, JM Rothberg, M Egholm, MJ Kozal. Low Abundance Drug Resistant Variants in Chronically HIV-Infected Antiretroviral Naïve Patients Significantly Impact Treatment Outcomes. J. Infect. Dis. 2009 Mar 1;199 (5):693-701.
•    FJ Palella, C Armon, K Buchacz, SR Cole, JS Chmiel, RM Novak, K Wood, AC Moorman, JT Brooks and the HIV Outpatient Study (HOPS) Investigators. The Association of HIV Susceptibility Testing with Survival among HIV-Infected Patients Receiving Antiretroviral Therapy: A Cohort Study. Ann Internal Med. 2009 July 21;151 (2):73-84.
• B Swanson, BE Sha, JK Keithley, L Fogg, J Nerad, RM Novak, O Adeyemi. Lipoprotein particle profiles by nuclear magnetic resonance spectroscopy in medically underserved HIV-infected persons. Journal of Clinical Lipidology, 2009, December, 3 (6): 379-384. AB Trotter, N Bhayani, R Florsheim and RM Novak
• Implementing Universal Oral HIV Screening in an Urban Emergency Department - Do Demographic Characteristics Impact Acceptance to Testing? Clin Infect Dis. 2010 January 15, 50:283.
•    K Buchacz, R Baker, FJ. Palella, JS Chmiel, KA Lichtenstein, RM Novak, KC Wood, JT Brooks, and the HOPS Investigators AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS 2010. 24:1549-1559. 
• DR Boulware, K Huppler Hullsiek, CE. Puronen, A Rupert, JV Baker, MA French, PR Bohjanen, RM Novak, JD Neaton and I Sereti for the INSIGHT Study Group. Higher Levels of CRP, D-dimer, IL-6 and Hyaluronic acid before Initiation of Antiretroviral Therapy (ART) are associated with Increased Risk of AIDS or Death. J Infect Dis. 2011 Jun;203(11):1637-1646.
•    B Swanson, JK Keithley, BE Sha, L Fogg, J Nerad, RM Novak, O Adeyemi, GT Spear. Policosanol for the management of HIV-related dyslipidemia in a medically underserved population: a randomized, controlled clinical trial. Alternative Therapies 2011. 17:30-35.
•  DL Pitrak, R Estes, RM Novak, M Linares-Diaz, JM Tschampa. Beneficial Effects of a Switch to a Lopinavir/ritonavir-Containing Regimen for Patients with Partial or No Immune Reconstitution with Highly Active Antiretroviral Therapy (HAART) Despite Complete Viral Suppression. AIDS Res Hum Retroviruses. 2011. 27:1-9.
• FJ Palella; RK Baker, K Buchacz, JS Chmiel, EM Tedaldi, RM Novak, MD Durham, JT Brooks and the HOPS Investigators. Increased Mortality among Publicly Insured Participants in the HIV Outpatient Study (HOPS) Despite HAART Treatment. AIDS 2011. 25(15): 1865-76.
• K. Buchacz, Douglas J. Ward, Rose K. Baker, Frank Palella, Joan Sander Chmiel, Benjamin Young, Bienvenido G. Yangco, RM. Novak and J. Brooks. Trends in Decline of Antiretroviral Resistance among ARV-experienced Patients in the HIV Outpatient Study (HOPS): 1999-2008. AIDS Res Treat. 2012;2012:230290.
• RM Novak, JT Richardson, K Buchacz, JS Chmiel, MD Durham, FJ Palella, A Wendrow, K Wood, B Young, JT Brooks and the HOPS Investigators7Immune Reconstitution Inflammatory Syndrome (IRIS) in the HIV Outpatient Study (HOPS): Incidence and Implications for Mortality. AIDS 2012; 6: 721 - 730.
• Metch B, Frank I, Novak R, Swann E, Metzger D, Morgan C, Lucy D, Dunbar D, Graham P, Madenwald T, Escamilia G, Koblin B. Recruitment of Urban US Women at Risk for HIV Infection and Willingness to Participate in Future HIV Vaccine Trials. AIDS Behav. 2012 Oct 23.
• GE Martin, GE, M Gouillou, AC Hearps, TA Angelovich, AC Cheng AC, F Lynch F, WJ Cheng
• G Paukovics, CS Palmer, RM Novak, A Jaworowski, AL Landay and SM Crowe. Age-associated changes in monocyte and innate immune activation markers occur more rapidly in HIV infected women. PLOS One. 2013; 8(1):e55279
• MJ McElrath, K Smythe, J Randolph-Habecker, KR Melton, TA Goodpaster, S Hughes, M Mack, A Sato, G Diaz, G Steinbach, RM Novak, M Curlin, J Lord, J Maenza, A Duerr, N Frahm, and F Hladik. CCR5+ macrophages are greatly enriched in human rectum compared to colon. J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):263-71. PMID: 23392465
•  HM Makinde, R Zariffard, P Mirmonsef, RM Novak, O Jarrett, AL Landay, GT Spear. IL-22 is Induced in the Lower Genital Tract During Trichomonas Vaginalis Infection. Am J Reprod Immunol. 2013 Jul;70(1):38-44. PMID: 23445169
• BA Koblin, B Metch, RM Novak, C Morgan, D Lucy, D Dunbar, P Graham, E Swann, T Madenwald, G Escamilia, I Frank, and the HVTN 906 study team. Feasibility of identifying a cohort of US women at high risk for HIV infection for HIV vaccine efficacy trials: Longitudinal results of HVTN 906. J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):239-44. PMID: 23446497
• RM Novak, B Metch, S Buchbinder,R Cabello, Y Donastorg, J-P Figoroa, H Abdul-Jauwad, P Joseph, E Koenig, D Metzger, M Sobieszycz, M Tyndall, C Zorilla. Risk Behavior among Women enrolled in a Randomized Controlled Efficacy Trial of an Adenoviral Vector Vaccine to Prevent HIV Acquisition: the Step Study. AIDS, 2013 Jul 17;27(11):1763-70. PMID: 23807272
• SM Hammer, ME Sobieszczyk, H Janes, ST Karuna, MJ Mulligan, D Grove, BA Koblin, SP Buchbinder, MC Keefer,GD Tomaras, N Frahm, J Hural, C Anude, BS Graham, ME Enama, E Adams, E DeJesus, RM Novak, I Frank, C Bentley, S Ramirez, R Fu, RA. Koup, JR Mascola, GJ Nabel, DC. Montefiori, J Kublin, M. Juliana McElrath, L Corey and PB Gilbert, for the HVTN 505 Study Team. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. N Engl J Med. 2013 Nov 28;369(22):2083-92. PMID: 24099601
•  KM Birse, A Burgener, GR Westmacott, S Morrister. RM Novak and TB Ball. Unbiased proteomics analysis demonstrates significant variability in mucosal immune factor expression depending on the site and method of collection. PLoS One. 2013 Nov 14;8(11):e79505. PMID: 24244515
• LR McKinnon, SM Hughes, SC De Rosa, JA Martinson, J Plants, KE Brady, PP Gumbi, DJ Adams, L Vojtech, CG Galloway, M Fialkow, G Lentz, D Gao, Z Shu, B Nyanga, P Izulla,
• J Kimani, S Kimwaki, A Bere, Z Moodie, AL Landay, JS Passmore, R Kaul, RM Novak, MJ McElrath, F Hladik. Optimizing Viable Leukocyte Sampling from the Female Genital Tract for Clinical Trials: An International Multi-Site Study. PLoS One 2014 January; 9 (1):  e85675. PMID: 24454917
•  FJ Palella Jr, C Armon, K Buchacz , JS Chmiel, RM Novak, RT D’Aquila and JT Brooks and HOPS Investigators. Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS). J Antimicrob Chemother doi:10.1093/jac/dku190
• P Patel, C Armon, JS Chmiel, JT Brooks, K Buchacz, K Wood, and RM Novak. Factors Associated With Cancer Incidence and With All-Cause Mortality After Cancer Diagnosis Among Human Immunodeficiency Virus-Infected Persons During the Combination Antiretroviral Therapy Era. Open Forum Infectious Diseases, DOI: 10.1093/ofid/ofu012
• SY Turin, RE Rosenfield, M Lee, K Patel, RM Novak. Feasibility of Universal HIV Testing in an Outpatient Clinic. Clin Infect Dis. 2014 Jul 14. pii: ciu554.

Monographs And Book Chapters:

• Clinical Management of the HIV-Infected Adult: A Manual for Mid-Level Clinicians. S. Thompson, R. Novak and K. Pursell, Eds. Emory AIDS Training Network, MATEC and DHHS, 1993, revised 1994.
• C. Yang, S. Cai, T. Holzer, R. Novak and C. Pidgeon. "Introduction to the Human Immunodeficiency Virus" in Tutorials for Biomedical Scientists, Ed. C. Pidgeon. VCH Publishers, New York, NY , 1996.
• C. Yang, T. Holzer, R. Novak and C. Pidgeon. "Measurements of HIV Viral Load by Polymerase Chain Reaction (PCR). in Tutorials for Biomedical Scientists, Ed. C. Pidgeon. VCH Publishers, New York, NY 1996.

Book Reviews And Review Articles:

• R.M. Novak. Something for Everybody: AIDS Testing, (2nd edn). Trends in Microbiol., 3:448-9.1995
• R.M. Novak. Human Immunodeficiency Virus:Biology, Immunology and Therapy. Perspectives in Biology and Medicine, 47(2):305-7, 2004
• R.D. MacArthur and R.M. Novak. Maraviroc: The First of a New Class of Antiretroviral Agents. Clin Infect Dis. July 15;47(2):236-41. 2008.
• G. Reid and R.M. Novak (2011). HIV-1 Treatment-Experienced Patients: Treatment Options and Management, Recent Translational Research in HIV/AIDS, Yi-Wei Tang (Ed.), ISBN: 978-953-307-719-2, InTech. 2011.
• F.G. Lynch, A. Styczynski, R.M. Novak. A History of Microbicides and Their Current Development Pipeline. Drugs of the Future, 36(12): 909-918. 2011.

Invited lectures:

• Conference Moderator, Gram Negative Resistance Forum: A National Nosocomial Resistance Surveillance Group Program. Chicago, IL, January, 1991
• Michael Reese Hospital, Chicago, IL, September, 1991: Update on HIV Disease
• Chicago Medical Society 47th Midwest Clinical Conference, March, 1991: The Retroviral Diseases
• Osler Institute Review of Internal Medicine, Rosemont, IL, December, 1991: Review of HIV Disease. Clinical Aspects
• St. Francis Hospital, Evanston, IL, August, 1992: Clinical Management of HIV Disease
• Lutheran General Hospital, Park Ridge, IL, February, 1994: Clinical Management of HIV Disease
• Chicago Medical Society 50th Midwest Clinical Conference, March, 1994: Prophylaxis of AIDS-Related Opportunistic Infections: An Update.
• Academy of Family Physicians, Cabrini Hospital, Chicago, IL, February, 1995: Management of HIV Disease
• Westlake Hospital Grand Rounds, Cicero, IL, February, 1995: Clinical management of HIV disease
• Academy of Family Physicians, Naperville, IL, March, 1995: New Problems in Infectious Diseases
• D4T and 3TC: The 3TC Expanded Access Experience. Bristol-Myers AIDS Investigator's Meeting, February, 1996, San Diego, CA.
• Protease Inhibitors. Twins Cities Infectious Diseases Group, Minneapolis, MN, April, 1996.
• Update from the XI Int'l Conference on AIDS. AIDS Research Alliance of Chicago, Chicago, IL, August, 1996.
• HIV Update: St. Vincent's Hospital Grand Rounds, Toledo, Ohio, November, 1996
• Antiviral Treatment Strategies: Henry Ford Hospital ID. Conference, Detroit, MI, December, 1996.
• Hepatitis Overview: Kishwaukee Community Hospital, DeKalb, IL, January, 1997
• Update on HIV: Hampton VA Hospital, Hampton VA, March, 1997
• Management of HIV Drug Resistance: Phone Conference, Milwaukee, Wisconsin, October, 1999
• Update in HIV Management. Christ Hospital, April, 2000
• Effect of Change from TID to BID Nelfinavir (NFV) on Viral Load, CD4 Count and Adherence. XIII Int’l AIDS Conference, Durban South Africa, July, 2000.
• Durban Update: Chicago Health Outreach, August, 2000
• Durban Update: Illinois Masonic, August, 2000
• Antiretroviral Drug Resistance: Clinical Management of HIV and STDS, Springfield, IL, September, 2000
• Adherence to Antiretroviral therapy: National Conference on Correctional Medicine, St. Louis, MO, October, 2000.
• Update on HIV Vaccine Research. At HIV Spring Update, Miami, FL, March, 2001
• Retrospective Review of Kaletra/Delaverdine for Salvage Therapy: Rescriptor Advisory Meeting, Sonoma, CA, August, 2001
• Recruitment and Retention of Women at Heterosexual Risk for HIV infection: HIV Vaccine Trials Network Quarterly Group Meeting, Seattle, WA, October, 2001
• Management of HIV, 2001. Seattle, WA, October, 2001.
• HIV Treatment Error Reduction Using a Genotype Database. HRSA and AHRQ Consultative Meeting on the Use of Technology in HIV Care, Rockville, MD, November, 2001.
• Management of HIV, Detroit, MI, January, 2002
• HIV Vaccine Update. 7th Annual Current Issues in HIV Pharmacotherapy, June 27, 2002, Oak Brook, IL.
• HIV Treatment Lectures, Jakarta, Indonesia, July, 2003
• Prevalence of Primary HIV Resistance in Treatment Naïve Patients in CPCRA 058: FIRST Trial: CPCRA Group Meeting, Washington, D.C., November, 2003.
• HIV and Hepatitis C, Phnom Penh, Cambodia, July, 2004
• Prevalence of Primary HIV Resistance in Treatment Naïve Patients in CPCRA 058: FIRST Trial: NIAID Grand Rounds, April, 2005.
• Keynote Speaker: Antivirals Update, 2005 MATEC Fall AIDS Meeting, Detroit, MI, November 15, 2005
• Medical Grand Rounds: HIV Update, 2006. Southern Illinois University Medical; School, Springfield, IL, March, 2006
• Pediatrics/Gyne Grand Rounds: HIV Vaccine Update. Mount Sinai Hospital, Chicago, IL. April, 2008
• Ob/Gyne Grand Rounds: HIV Vaccine Update. Stroger Cook County Hospital, August, 2008.
• Annual Internal Medicine Conference: HIV Disease Management, Kathmandu, Nepal, November, 2009
• Update in Internal Medicine Course: HIV Update. State College, Pennsylvania, September, 2010.
• Immunization Update. Vista Medical Center/Victory Memorial Hospital, Waukegan, IL, March, 2011.
• HIV Vaccines. 20th Annual HIV/STD Conference, Springfield, IL. September, 2011
• HIV Care in limited Resource Settings: Health Leads: Sickcare Vs. Healthcare: Envisioning a Healthy Chicago.
• U. of Chicago School of Social Service Administration, April, 2014